The CD6/CD318 axis is currently being investigated for its potential involvement in type 1 diabetes (T1D), particularly in modulating the activation of autoreactive T cells that attack insulin-producing beta cells in the pancreas. Here, INS is linked to type 1 diabetes mellitus.